AIM
NBIX icon

AIA Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

AIA Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$15K Hold
155
– – ﹤0.01% 412
2020
Q2 		$19K Buy
+155
New +$17.1K ﹤0.01% 348

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AIA Investment Management's NBIX Position: Q3 2020 in Review

AIA Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q3 2020 at 155 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #412.

AIA Investment Management first reported a position in NBIX in Q2 2020 and has held it in 2 quarters since. The position peaked at $19K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • AIA Investment Management held 155 shares of Neurocrine Biosciences worth $15K as of Q3 2020.
  • AIA Investment Management left its Neurocrine Biosciences share count unchanged in Q3 2020.
  • Neurocrine Biosciences made up ﹤0.01% of AIA Investment Management's portfolio in Q3 2020, its #412 holding.
  • AIA Investment Management first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 2 quarters since.
  • AIA Investment Management's Neurocrine Biosciences position peaked at $19K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.